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RESEARCH ARTICLE Open Access
The effect of a pharmaceutical transitional
care program on rehospitalisations in
internal medicine patients: an interrupted-
time-series study
Fatma Karapinar-Çarkıt1* , Sander D. Borgsteede2, Marjo J. A. Janssen1, Marlies Mak1, Nimet Yildirim1,
Carl E. H. Siegert3, Peter G. M. Mol4, Toine C. G. Egberts5,6 and Patricia M. L. A. van den Bemt7*
Abstract
Background: Medication errors at transition of care can adversely affect patient safety. The objective of this study is
to determine the effect of a transitional pharmaceutical care program on unplanned rehospitalisations.
Methods: An interrupted-time-series study was performed, including patients from the Internal Medicine department
using at least one prescription drug. The program consisted of medication reconciliation, patient counselling at discharge,
and communication to healthcare providers in primary care. The primary outcome was the proportion of patients with an
unplanned rehospitalisation within six months post-discharge. Secondary outcomes were drug-related hospital visits,
drug-related problems (DRPs), adherence, believes about medication, and patient satisfaction. Interrupted time series
analysis was used for the primary outcome and descriptive statistics were performed for the secondary outcomes.
Results: In total 706 patients were included. At 6months, the change in trend for unplanned rehospitalisations between
usual care and the program group was non-significant (− 0.2, 95% CI -4.9;4.6). There was no significant difference for drug-
related visits although visits due to medication reconciliation problems occurred less often (4 usual care versus 1
intervention). Interventions to prevent DRPs were present for all patients in the intervention group (mean: 10
interventions/patient). No effect was seen on adherence and beliefs about medication. Patients were significantly
more satisfied with discharge counselling (68.9% usual care vs 87.1% program).
Conclusions: The transitional pharmaceutical care program showed no effect on unplanned rehospitalisations.
This lack of effect is probably because the reason for rehospitalisations are multifactorial while the transitional
care program focused on medication. There were less hospital visits due to medication reconciliation problems,
but further large scale studies are needed due to the small number of drug-related visits. (Dutch trial register:
NTR1519).
Keywords: Patient discharge, Continuity of care, Medication reconciliation, Patient education, Medication errors,
Hospital readmission
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Background
Medication errors occur frequently at transition of care
and can negatively affect patient safety [1]. Four key fac-
tors contribute to these errors. The first factor is the lack
of complete sources to assess patients’ medication use.
In combination with patients’ recall bias this results in
incorrect prescriptions at hospital admission [2]. These
admission errors can carry over to the discharge medica-
tion. The second factor is insufficient evaluation of the
pharmacotherapy. For example, when temporarily dis-
continued medication is forgotten and not restarted (e.g.
anticoagulants). Or medication intended for temporary
use are continued (e.g. hypnotics, proton-pump inhibi-
tors) [3]. The third factor is insufficient patient involve-
ment. Hospitalised patients often get help with the
administering of their medication by hospital staff. After
hospital discharge, patients are abruptly expected to
manage their medication themselves, generally with little
preparation [4]. The last factor regards insufficient com-
munication from hospital to primary care. Discharge let-
ters and prescriptions generally do not contain the
entire pharmacotherapy and changes therein [5, 6]. Both
the general practitioner and community pharmacy lack
information of reasons for all changes, making it unclear
whether changes should be maintained, were only tem-
porary or were unknown to hospital staff [7, 8].
Transitional care programs, focusing on the transition
from hospital to the community setting, have been devel-
oped. Evidence exists that interventions around discharge
medication can reduce adverse events, reduce rehospitali-
sations and improve adherence [9–14]. However, some
studies showed no effect and Holland et al. reported
contradictory results on the rate of rehospitalisations
[15–17]. Most studies have implemented single inter-
ventions using educational strategies or medication rec-
onciliation [9, 11, 18–23]. However, to address all four
key factors, as stated above, requires multiple interven-
tions to affect transition of care-related medication errors.
Therefore, the COACH (Continuity Of Appropriate
pharmacotherapy, patient Counselling and information
transfer in Healthcare) program has been designed by
combining interventions. The aim of this study is to deter-
mine the effect of the COACH program on unplanned
rehospitalisations within six months after discharge from
an Internal Medicine department.
Methods
Design
This was a prospective interrupted time-series study at a
general teaching hospital; OLVG (formerly Sint Lucas
Andreas Hospital), Amsterdam, The Netherlands. This
is a quasi-experimental study that is characterized by a
series of measurements over time interrupted by an
intervention [24]. We regarded a randomized design as
not feasible, because we changed how care was orga-
nised and previous experiences with pilot projects have
shown that the COACH program contaminates usual
care as residents and other healthcare providers learn
from the COACH program. The program therefore
influences prescribing behaviour. Therefore, we have
chosen for a study with a before-after design including
interrupted time series as the preferred alternative.
During eight months usual care patients were included
(Fig. 1). During an intermediate period of 3.5 months the
COACH program was introduced. Patients were again
included during a nine month post-intervention period,
once the program had settled in. The study protocol has
been described elsewhere [25].
This study was submitted to the Institutional Medical
Ethics Committee of the Sint Lucas Andreas Hospital
and exempted from review by the committee as this is
not required for studies that do not affect the patient’s
integrity (according to Dutch legislation). Patient data
were obtained and handled in accordance with privacy
regulations. Patients provided written informed consent
for the study (reference number of the study mec09/005).
Study population
All admitted patients to the Internal Medicine depart-
ment with at least one prescribed drug intended for
chronic use were invited to participate. Exclusion criteria
were: no informed consent, no medication prescribed at
discharge, died during index admission, lived outside the
catchment area of the hospital (as we were unable to
obtain rehospitalisation data), transfer to another de-
partment, hospital or nursing home (because these
patients are not responsible for medication use them-
selves), discharge within 24 h or out of office hours,
impossibility to counsel (as stated by the resident due
to physical/mental constraints, being critically ill or
due to language restrictions without relatives or
healthcare personnel to translate). Patients could be
included in the study only once.
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Usual care
At hospital admission and discharge, medication recon-
ciliation was not performed structurally (Fig. 1). Resi-
dents mostly used the information provided by patients,
carers, or previous hospital records to prescribe the
medication. Residents could consult community phar-
macy medication records. A clinical pharmacist checked
prescribed medication for correct dosages, the presence
of double medication, or potential drug-drug interac-
tions and contra-indications using the Computerized
Physician Order Entry (CPOE) system.
Residents and nurses performed patient counselling at
hospital discharge to explain medication changes if
regarded necessary. Discharge medication information
was communicated to the general practitioner (GP) and
community pharmacy. This communication contained
little or no information on (reasons for) changes in the
pharmacotherapy.
In the Netherlands, community pharmacists and general
practitioners are frequently linked to each other. When a
community pharmacist changes a medication record in
their information system, this information is automatically
communicated electronically to the general practitioner.
COACH intervention program
A team of pharmaceutical consultants carried out the
COACH program with clinical pharmacists as supervi-
sors. Pharmaceutical consultants are specialized phar-
macy technicians who have followed an additional three
year bachelor program focusing on pharmaceutical pa-
tient care. Therefore, they are educated in medication
errors and communication with patients. In the hospital
they have followed a training program to perform medi-
cation reconciliation.
At hospital admission and discharge, medication rec-
onciliation was performed by verifying the admission
and discharge prescriptions of the resident in the hospi-
tal’s CPOE with community pharmacy records and
assessing patient information. Discrepancies with the
pre-admission medication and possible drug-related prob-
lems were communicated to the resident using a protocol
[25]. The resident adjusted the prescriptions if necessary.
At hospital discharge, the pharmaceutical consultant
counselled the patient/carer using a medication sum-
mary that contained all known pharmacotherapy and
(reasons for) medication changes. The same information
was faxed to the community pharmacy before discharge.
The resident could upload this information into the dis-
charge letter for the general practitioner. Every (new)
resident was trained in the research protocol and the
study flow was presented on a poster in their office.
Study endpoints and data collection
The primary outcome was the proportion of patients
with at least one unplanned rehospitalisation within six
months after discharge. An unplanned rehospitalisation
was defined as an unscheduled hospitalisation, which
occurred after discharge, to the OLVG Hospital or any
other hospital within the catchment area. Other hospital
contacts, i.e. planned rehospitalisations and emergency
department visits, and mortality were regarded as sec-
ondary outcomes. These data were manually collected
using the hospital information systems of OLVG and
five other hospitals.
Exploratory outcomes included the interventions per-
formed to prevent drug-related problems (DRPs), adher-
ence to drug treatment, patients’ attitude towards drugs,
patients’ satisfaction with information about medicines
Fig. 1 Timeline of the COACH program and of the introduction and implementation of the program. a discrepancies between medication
prescribed pre-admission and medication prescribed in the hospital. CP = community pharmacy, DRPs = drug-related problems, ED = emergency
department, GP = general practitioner, PC = patient counselling, MR =medication reconciliation, t = 0,1,6: respectively, at discharge,1 month after
discharge and 6months after discharge
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and patients’ general satisfaction with counselling. Inter-
ventions performed to prevent DRPs were extracted
from the checklists used by pharmaceutical consultants
and classified according to a previously described classi-
fication system [26].
Before discharge, patients were requested to fill out
validated questionnaires with a 5-point Likert scale about
their adherence to drug treatment (MARS; Medication
Adherence Rating Scale), their attitude towards drugs
(BMQ; Beliefs about Medicines Questionnaire), satisfac-
tion with information about medicines (SIMS) and their
general satisfaction with counselling [27–31]. After one
month, a second short questionnaire with MARS and
BMQ was sent. Patients were phoned if they had given
informed consent to fill out questionnaires but failed to
respond (three attempts).
Also, a post-hoc analysis was performed to assess the
proportion of patients with drug-related hospital visits.
A drug-related visit was defined as any admission or
emergency department visit related to the use of a drug.
An Internist and a Hospital pharmacist/Clinical pharma-
cologist assessed whether all revisits (n = 424) were drug-
related and whether these readmissions were potentially
preventable using a blinded consensus method [32].
From the hospital information system we extracted
baseline characteristics including gender, age, co-
morbidities, length of stay, and previous hospital con-
tacts in the six months before inclusion. The Charlson
co-morbidity score was used to evaluate the severity of
co-morbidities [33]. This score was previously associ-
ated with hospitalisations [33, 34].
Fidelity of the intervention (i.e. whether all parts of the
intervention are implemented as planned) was also
assessed manually. The number of paper checklists that
pharmaceutical consultants used to perform medication
reconciliation at hospital admission and discharge and
patient counselling at hospital discharge were counted.
For the information exchange to the community pharma-
cist we counted the number of discharge medication over-
views. For the information exchange to the general
practitioner, we checked whether the residents uploaded
the discharge medication information, prepared by the
pharmaceutical consultant, into the discharge letter.
Sample size
Results of previous studies into pharmacist pre-discharge
medication reconciliation combined with patient counsel-
ling vary widely [11, 12, 14, 35–37]. Four studies report an
absolute decrease of rehospitalisation frequency of 13–
30% and two studies report 5–9% (median 15%). However,
the populations in these studies are not fully comparable:
previous studies were limited to elderly patients and our
study also included younger patients. Therefore, a conser-
vative approach was used: 20% of rehospitalised patients
in usual care and 12% in the intervention group (8% abso-
lute reduction). With a type 1 error of 0.05, a power of
80%, a total of 360 patients per group was needed.
Data analysis
Patients were compared using the independent t-test for
continuous variables and the chi-square test for frequen-
cies. For the interrupted time series analyses we col-
lected data over an 8-month period with usual care and
over a 9-month intervention-period with the COACH
program in place. The data points for the time-series
were aggregated per four weeks. For example, for un-
planned rehospitalisations the number of patients with
an unplanned rehospitalisation was divided by the total
number of patients included in that data point. As there
was only a small number of patients included in the last
month in both periods, these patients were added to the
previous month. Thus, there were 7 data points for the
usual care-period and 8 data points for the intervention-
period. The study design met EPOC criteria for a robust
interrupted time series analysis, that is at least three
data-points before and after the intervention, each
consisting of at least 30 patients [38]. Segmented linear
regression analysis was used to assess a trend for the
percentage of patients with above mentioned outcomes.
Durbin-Watson statistics and visual inspection of the
residuals versus time were used to check for possible
autocorrelation (serial correlation between an outcome
and consecutive observations, non-significant Durbin-
Watson means no autocorrelation). To estimate the level
and trend of the outcomes in the usual care-period and
to estimate the changes in level and trend after the im-
plementation of the COACH program, the following lin-
ear regression model was used [24].
Yt= β0 + β1 * timet + β2 * interventiont + β3 * time
after interventiont + et
β0 = usual care level of the outcome (value at time
zero)
β1 = slope prior to the intervention (usual care trend)
β2 = change in outcome immediately after the
intervention
β3 = change in the slope from before to after the
intervention
Potential confounders were added to this model to
evaluate the impact of imbalances in the case-mix in the
usual care- and intervention-period.
Descriptive and comparative statistics (i.e. t-test, chi-
squared test) were performed for the other outcomes as
described in previous studies [26–31].
Results
A total of 2274 patients were screened; 1568 (69%) pa-
tients were excluded (Fig. 2), leaving 706 patients (341
usual care, 365 COACH program) who were included.
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The main reason for exclusion were discharge within 24
h or out-of-office hours (19.4%), transfer (16.8%) and no
medication use (15.6%).
Patients who did not give informed consent were sig-
nificantly older (68.7 vs 65.5 years, p = 0.02) and stayed,
non-significantly, longer in hospital (11.2 vs 9.3 days,
p = 0.20). No difference was found for type of admission
(planned/unplanned) and gender.
The patients in the usual care- and intervention-
period differed in baseline characteristics (Table 1). Pa-
tients in the COACH program received more frequently
help with their medication use (18.8% vs 30.8%, p <
0.01), had more hospital contacts before inclusion (1.3
vs 1.7, p = 0.03) and had a higher number of co-
morbidities (3.4 vs 3.9, p < 0.01) which were also more
severe (p < 0.01).
Fidelity of the COACH intervention
At hospital admission and discharge, respectively, 91.8
and 100% of patients received medication reconciliation,
100% received patient counselling at discharge and for
100% medication related information was transferred to
Fig. 2 Flowchart of inclusion of patients participating in the usual care- and intervention-period
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Table 1 Characteristics of patients participating in the before- and after-period
aincludes one-day care, emergency department visits, planned and unplanned admissions in the last 6 months before inclusion
bincludes planned and unplanned admissions in the last 6 months before inclusion
ckidney function less than 60ml/min during at least 3 months
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community pharmacies (Table 2). At admission, in 8.2%
of patients medication reconciliation was not performed
due to a short hospital stay and medication reconcili-
ation was therefore performed at discharge.
For 102 patients (27.9%) the residents uploaded the in-
formation prepared by the pharmaceutical consultant,
the reconciled discharge medication overview, into the
discharge letter for general practitioners. However, 48
(13.2%) contained the exact same information as was
communicated to the patient and community pharma-
cists. Resident for example deleted information regard-
ing allergies or reasons for medication changes.
Unplanned rehospitalisations
The proportion of patients with an unplanned rehos-
pitalisation was 27.3% in the usual care vs 33.2% with
the COACH program in place. The Durbin Watson
statistics was not indicative for autocorrelation. In the
unadjusted segmented linear regression model the
baseline trend showed a non-significant decrease in
unplanned rehospitalisations (i.e. β1, − 1.7, 95% CI
-4.8; 1.4) in the usual care-period (Table 3). The
introduction of the COACH program was followed by
a non-significant increase of unplanned rehospitalisa-
tions (i.e. β2, 8.5, 95% CI -8.4; 25.5) and no change in
trend (i.e. β3, 2.3% rehospitalisations per 4 week
period 95% CI − 1.7; 6.3).
In the second segmented linear regression model we
adjusted for confounders (help with medication use, all
hospital contacts in the last 6 months, mean Charlson
score), but again non-significant results were found. β1
became − 2.1% (95% CI -5.2; 1.1), β2 increased to 12.7%
(95% CI -7.3; 32.7) and β3 was − 0.2% rehospitalisations
per 4 week period (95% CI -4.9-4.6), see Fig. 3 for the
proportion of patients with an unplanned rehospitalisa-
tion per study month.
Clinical outcomes
The proportion of patients with any rehospitalisation,
planned rehospitalisation and emergency department
visits did not differ (Table 4). Also, mortality did not dif-
fer (7.6% usual care vs 6.6% COACH program).
Intermediate outcomes
In 100% of patients at least one intervention was re-
corded aimed at preventing DRPs (mean: 10/patient,
Table 5). Medication reconciliation resulted in an aver-
age of 5.9 medication changes per patient: 3.9 due to dis-
crepancies between prescribed and actual medication
use and 2 due to optimizations in the pharmacotherapy
(e.g. discontinuation of hypnotics that were initiated in
the hospital). During patient counselling a mean of 4 in-
terventions were aimed to optimise the patient’s medica-
tion handling (e.g. answer questions regarding side
effects, discuss adherence).
The response rate for the questionnaires were low
(despite telephone calls). There was no significant differ-
ence found between groups for adherence, beliefs about
medication, and the satisfaction with information about
medication (see Table 4). Patients were significantly
more satisfied with the information provided by the
pharmaceutical consultant (68.9% vs 87.1%, p = 0.01).
Post-hoc analysis: drug-related revisits
Twenty-nine usual care patients (8.5%) had a total of 34
drug-related revisits versus 37 COACH program patients
(10.1%) with a total of 44 visits. The reviewers regarded
10 of 34 (29.4%) visits of usual care patients preventable
by the COACH program; 4 visits were due to medication
reconciliation problems and 6 visits due to an adherence
problem. For the COACH program patients 7 of 44
(15.9%) visits were regarded potentially preventable: 1
visit due to a medication reconciliation problem and 6
due to a possible adherence problem. The remaining
visits were regarded non-preventable (e.g. side effects,
worsening conditions, medication changes implemented
post-discharge).
Discussion
This study showed that the COACH program did not
decrease unplanned rehospitalisations. The program
identified interventions to prevent DRPs for every in-
cluded patient. Also, patients expressed a greater satis-
faction with the counselling performed. No effect was
seen on other exploratory outcomes. Drug-related visits
did not differ also, although the number of visits that
Table 2 Fidelity of the COACH program (n = 365)
Implementation of After-period (%) Performed by
Medication reconciliation at hospital admissiona 335 (91.8) Pharmaceutical consultant
Medication reconciliation at hospital discharge 365 (100.0) Pharmaceutical consultant
Patient counselling at hospital discharge 365 (100.0) Pharmaceutical consultant
Information exchange to community pharmacist 365 (100.0) Pharmaceutical consultant
Information exchange to general practitionerb 102 (27.9) Resident
afor the other 8.2% of patients medication reconciliation could not be performed due to a short hospitalisation
bfor 72.1% of patient the resident failed to upload the discharge medication overview into the discharge letter. If the discharge medication overview was
uploaded, the resident could adjust the information, e.g. delete information regarding allergies or contra-indications
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were potentially preventable with the COACH program
decreased from 29.4% in the before-period to 15.9% in
the after-period.
Although various transitional pharmaceutical care
studies showed a reduction in number of rehospitalisa-
tions, our study adds to the studies that did not. This
leaves thus an overall mixed picture of the effect of these
solely pharmaceutical programs [11, 37, 39–47]. Evi-
dence on components effective for specific pharmaceut-
ical transitional care programs is limited [48, 49].
There may be several reasons for our findings. First,
we did not define a high-risk group but included all
patients. Scullin et al. reported an 8% reduction in the
rehospitalisation frequency after one year in a RCT with
a pre-defined high-risk group (49% control vs 41% inter-
vention, p = 0.027) [37]. We chose to include all patients
because from a patient safety perspective every patient
should receive medication reconciliation to prevent
medication errors and patient counselling to prevent
misunderstanding of the medication changes in the hos-
pital. However, with the current knowledge, a larger
sample size was needed.
Second, the implementation fidelity for the COACH
program was low for informing the general practitioner
through the discharge letter. A study showed decreased
30-day readmission rates (odds ratio 0.61, 95% CI: 0.42–
0.88) for patients in whom the intervention was imple-
mented completely in the USA [50]. No decrease was
seen for patients who received only parts of the inter-
vention. In the COACH program, the sample size was
too small to perform relevant subgroup analysis. Fidelity
with informing the general practitioner with the exact
same information as was communicated to the patient
and community pharmacist was poorly performed by the
residents (27.9% of patients). Every resident received the
study protocol, training in how to insert the discharge
medication into the discharge letter, and feedback during
the study. However, the turn-over of residents was high,
the residents worked on several departments, and had
many tasks or were unaware that general practitioners
Table 3 Effect of COACH program on unplanned
rehospitalisations (n = 341 before and n = 365 after)
ITS unplanned rehospitalisation Unadjusted Adjusteda
β0, usual care level of the
outcome (95% CI)
34.0 (20.2; 47.9) 11.3 (− 28.7; 51.2)
β1, baseline trend (95% CI) -1.7 (− 4.8; 1.4) −2.1 (− 5.2; 1.1)
β2, change in outcome
immediately after the
intervention (95% CI)
8.5 (−8.4; 25.5) 12.7 (−7.3; 32.7)
β3, change in the slope
from before to after
the intervention(95% CI)
2.3 (−1.7; 6.3) −0.2 (−4.9; 4.6)
ITS interrupted time series analysis. β values were calculated using segmented
regression analysis
aAdjusted for baseline differences: help with medication use, all hospital
contacts in the last 6 months, mean Charlson score
Fig. 3 Impact of the COACH program on unplanned rehospitalisations per study month (adjusted for confounders)
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Table 4 Results of clinical outcomes and intermediate outcomes (patient questionnaires)
U = usual care: number of patients, I = intervention: number of patients, ITS = interrupted time series analysis, t = 0: at discharge, t = 1: 1 month after discharge
aSatisfaction with Information about Medicines Scale (SIMS). Higher scores indicate a higher degree of overall satisfaction (17 items: score range 0–17) [29].
bSelf-report Medication Adherence Rating Scale (MARS). Higher scores indicate higher adherence (5-items: score range 5–25) [30, 31].
cBeliefs about medication (BMQ). BMQ-necessity: higher scores indicate beliefs about the necessity and efficacy of medicines (5 items, score range 5–25). BMQ
concerns: higher scores indicate concerns about the harmful effects of medicines (6 items, score range 6–30). BMQ General-overuse and BMQ General-harm:
higher score indicate beliefs that medicines are over-used by doctors and are harmful addictive poisons (both 4 items, score range 4–20) [27, 28].
dPatient’s general satisfaction with counselling by the resident did not significantly differ between the before- and after-period
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want to be completely informed [7, 51]. The residents
used the standard link to include discharge medication
into the discharge letter that was a copy of the medication
list at discharge (without allergies and reason for medi-
cation changes). However, these allergies were already
present before hospital admission so we do not think
that allergies were missed by the general practitioner.
Furthermore, the fidelity with informing the commu-
nity pharmacist was 100%. Changes made by the com-
munity pharmacist in the patient’s medication record is
automatically communicated electronically to the pa-
tient’s general practitioner. The general practitioner
could miss the reasons for medication changes if the
community pharmacy did not document this in their
information system.
Third, our intervention might have been too narrow.
Previous studies with benefits on rehospitalisations had
a broader intervention (e.g. including also post-discharge
interventions), did not focus solely on the pharmacother-
apy (e.g. interventions on appointment schedules), or used
a combination of healthcare providers [35, 37, 50, 52–54].
Fourth, the rehospitalisation outcome was unrealistic.
It makes more sense that a program such as COACH
only influences drug-related visits, drug-related prob-
lems, adverse drug events or general healthcare usage by
patients, e.g. additional visits to the community phar-
macy or general practitioner for questions or problems
with medication. Two studies with transitional pharma-
ceutical care interventions reported no reduction in
overall rehospitalisations but a significant reduction in
drug-related rehospitalisations [42, 46]. We saw a non-
significant decrease in hospital visits due to a medication
reconciliation problem, but this was only shown in a
post-hoc analysis and our study was underpowered for
this outcome. We chose rehospitalisations as the primary
outcome, because policy makers are more interested in
clinical outcomes than in intermediate outcomes [55].
Finally, it is unknown to what degree the quality of
care after hospital discharge influences outcomes. For
example, we have shown that community pharmacies
and general practitioners fail to update their patient
records with discharge medication related information
[56, 57]. This can result in renewed prescribing of previ-
ously discontinued medication [6, 58, 59].
Previous studies also showed mixed results for adher-
ence [11, 39, 60–63]. In this study, patients reported very
high medication adherence with the MARS question-
naire which could lead to a ceiling effect. But it is more
likely that the one-time patient counselling at discharge
was not enough to improve the intermediate outcomes
such as adherence and beliefs about medication. Patients
were more satisfied with counselling by the pharmaceut-
ical consultant than the counselling by the resident. This
result corresponds with a previous qualitative study that
we performed [64].
The strength of this study was that we assessed rehos-
pitalisations to 6 hospitals, performed an interrupted-
time series analysis and we assessed various outcomes.
Limitations of this study also need to be discussed. First,
patients in the before- and after-period differed in base-
line characteristics. We adjusted for these. However,
there may be other confounding factors that we did not
measure and therefore could not adjust for (e.g. health
literacy). Second, patients who did not give informed
consent were significantly older and tended to stay lon-
ger in hospital, suggesting that patients who were more
severely ill refused to participate. It is expected that
these patient are rehospitalised more often, so the rehos-
pitalisation frequency may be underestimated. Third, as
this study concerns a monocenter study at one depart-
ment the generalizability is limited. Fourth, more data-
points for the interrupted time series analysis would be
desirable, but studies as ours are labour intensive and
the number of observations (patients with/without hos-
pitalisations) per data point had to be manually col-
lected. This is very different to e.g., studies that use
electronic health records or claims data. This number of
data points and follow up time (8 + 9 =) 17 months was
the maximum number feasible within the constraints of
our study budget. A recent publication of Jandoc et al.
acknowledges there is ‘no gold standard’ but suggests a
number of nine data points as a minimum considering










Elimination of discrepanciesa 1.65 (62.4) 1.43 (68.2) 0.82 (49.7) 3.90 (89.2)
Optimisation of pharmacotherapyb 0.10 (9.7) 1.76 (75.1) 0.15 (13.0) 2.02 (80.4)
Optimisation medication handlingc – – 4.15 (97.8) 4.15 (97.8)
Total 1.75 (64.1) 3.19 (93.4) 5.12 (98.9) 10.07 (100.0)
a Examples: omission of pre-admission used diabetes drug started at hospital admission, temporarily discontinued anticoagulant restarted at hospital discharge,
patient used a different dose of inhalation medication pre-admission
b Examples: a laxative added to opioid use at admission, analgesics or protonpumpinhibitor discontinued at discharge as there was no indication anymore,
patient states that sedative is no longer needed
c Examples: questions of patient regarding side effect answered, adherence to medication and helping tools discussed, medication changes explained
d Percent of patients for whom at least one intervention was registered
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variation and expected effect size [65]. The number of
nine is now also proposed in the updated EPOC guid-
ance [66]. Our study just falls short of this recommenda-
tion. Fifth, we had no control line to check how
rehospitalisations changed over time in our region. Hos-
pitals are under pressure to become more efficient and
readmissions are regarded a quality indicator. That could
decrease the readmission rate over years. However, in
the Netherlands, the elderly patient population is in-
creasing which also increases rehospitalisations in this
patient group. Sixth, we performed a post-hoc analysis
for the drug-related visits. Finally, patients did not want
to fill out questionnaires as they considered this as a
burden or they were not interested in research. The
sample size with respect to the questionnaires was lim-
ited and the results may be biased as patients who were
more interested in the study might have participated.
Future studies need to assess what effective compo-
nents are and should assess clinical outcomes that are
more sensitive to pharmaceutical care interventions, e.g.
drug-related readmissions and adverse drug events. Also,
studies need to improve continuity of care after dis-
charge by primary healthcare providers. Future research
should first consider the sensitivity of the measured out-
come. Decision makers could come to the conclusion
that interventions do not work while studies are under-
powered and cannot show an effect.
Conclusions
The transitional care program, COACH, did not de-
crease unplanned rehospitalisations of Internal Medicine
patients. Interventions to prevent DRPs were recorded
in all patients and patient satisfaction increased.
The lack of effect on unplanned rehospitalisations
could be due to the included population (all patients vs
high risk), intervention (pharmaceutical or more com-
prehensive), follow-up (no post-discharge follow up vs
home visits or phone calls implemented post-discharge)
and outcome (all rehospitalisations vs drug-related re-
hospitalisations).
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